Inventor · disambiguated record
Karla Drescher
Also filed as: DRESCHER KARLA
52 granted patents·25 pending applications·185 citations·filing 1995–2019
97Inventor score
Top patents by PatentIndex Score
77 records- 0193US9273068B2Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10AABBOTT GMBH & CO KG·Filed 2012·Granted Mar 1, 2016·25 cites·44 claims
- 0290US8076326B2N-phenyl- (piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorHAUPT ANDREAS·Filed 2010·Granted Dec 13, 2011·23 cites·28 claims
- 0388US8440694B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptorTURNER SEAN COLM·Filed 2012·Granted May 14, 2013·12 cites·13 claims
- 0487US10118926B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Nov 6, 2018·10 cites·6 claims
- 0587US6919342B2Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2004·Granted Jul 19, 2005·17 cites·15 claims
- 0683US9938269B2Inhibitor compounds of phosphodiesterase type 10AGENESTE HERVE·Filed 2012·Granted Apr 10, 2018·7 cites·33 claims
- 0783US8183237B2Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorHAUPT ANDREAS·Filed 2010·Granted May 22, 2012·4 cites·17 claims
- 0880US8343959B2N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorABBOTT GMBH & CO KG·Filed 2011·Granted Jan 1, 2013·5 cites·10 claims
- 0980US7790727B2Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorABBOTT GMBH & CO KG·Filed 2008·Granted Sep 7, 2010·4 cites·31 claims
- 1076US7851463B2Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorABBOTT GMBH & CO KG·Filed 2005·Granted Dec 14, 2010·2 cites·21 claims
- 1176US7320979B2N-[(piperazinyl)hetaryl]arylsulfonamide compoundsABBOTT GMBH & CO KG·Filed 2004·Granted Jan 22, 2008·7 cites·22 claims
- 1275US9790203B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 17, 2017·2 cites·26 claims
- 1375US9200005B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Dec 1, 2015·3 cites·23 claims
- 1475US9169253B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2013·Granted Oct 27, 2015·1 cites·23 claims
- 1574US9388180B2Inhibitor compounds of phosphodiesterase type 10AABBOTT GMBH & CO KG·Filed 2013·Granted Jul 12, 2016·3 cites·37 claims
- 1674US8242102B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorTURNER SEAN COLM·Filed 2008·Granted Aug 14, 2012·2 cites·23 claims
- 1773US9856220B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2016·Granted Jan 2, 2018·1 cites·26 claims
- 1873US9573950B2Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulatorsABBVIE DEUTSCHLAND·Filed 2015·Granted Feb 21, 2017·2 cites·48 claims
- 1973US8969552B2Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Mar 3, 2015·2 cites·25 claims
- 2072US8362010B2Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorABBOTT GMBH & CO KG·Filed 2010·Granted Jan 29, 2013·2 cites·23 claims
- 2171US8232426B2Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorDRESCHER KARLA·Filed 2005·Granted Jul 31, 2012·1 cites·19 claims
- 2269US9475808B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2015·Granted Oct 25, 2016·1 cites·33 claims
- 2369US9163019B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2014·Granted Oct 20, 2015·1 cites·26 claims
- 2468US9388148B2Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptorABBVIE DEUTSCHLAND·Filed 2014·Granted Jul 12, 2016·1 cites·6 claims
- 2568US8507469B2Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptorSCHULTZ THOMAS·Filed 2008·Granted Aug 13, 2013·2 cites·44 claims
- 2668US6444674B1Substituted pyrimidine compounds and the use thereofABBOTT LAB·Filed 2001·Granted Sep 3, 2002·3 cites·15 claims
- 2766US6342604B1Substitute pyrimidine compounds and the use thereofBASF AG·Filed 1995·Granted Jan 29, 2002·22 cites·28 claims
- 2865US8101754B2Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorUNGER LILIANE·Filed 2005·Granted Jan 24, 2012·1 cites·21 claims
- 2965US6403593B1Triazole compounds and the use thereofABBOTT LAB·Filed 2000·Granted Jun 11, 2002·3 cites·19 claims
- 3064US2019048007A1Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 3161US2010210664A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorTURNER SEAN COLM·Filed 2008·Application pending·0 cites
- 3261US2015175570A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorABBVIE DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 3360US2010152179A9Treatment of central nervous system disordersABBOTT LAB·Filed 2008·Application pending·0 cites
- 3459US2014200224A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorABBVIE DEUTSCHLAND·Filed 2013·Application pending·0 cites
- 3558US9994568B2Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2015·Granted Jun 12, 2018·0 cites·28 claims
- 3658US9464072B2Treatment of central nervous system disordersABBVIE INC·Filed 2014·Granted Oct 11, 2016·0 cites·11 claims
- 3758US8293913B2Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptorTURNER SEAN COLM·Filed 2008·Granted Oct 23, 2012·0 cites·13 claims
- 3858US6124294ATriazole compounds and the use thereofBASF AG·Filed 1995·Granted Sep 26, 2000·16 cites·9 claims
- 3957US2020283439A1Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 4055US10308610B2Inhibitor compounds of phosphodiesterase type 10AABBVIE DEUTSCHLAND·Filed 2017·Granted Jun 4, 2019·0 cites·22 claims
- 4155US2019071443A1Tricyclic quinoline and quinoxaline derivativesABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 4255US2007054918A1N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptorBRAJE WILFRIED·Filed 2004·Application pending·0 cites
- 4354US2013116241A1Novel inhibitor compounds of phosphodiesterase type 10aABBOTT GMBH & CO KG·Filed 2012·Application pending·0 cites
- 4454US2013116229A1Novel inhibitor compounds of phosphodiesterase type 10aABBOTT GMBH & CO KG·Filed 2012·Application pending·0 cites
- 4553US2004204422A1N-[(Piperazinyl)hetaryl]arylsulfonamide compoundsABBOTT GMBH & CO KG·Filed 2003·Application pending·0 cites
- 4653US2011319421A1Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptorTURNER SEAN COLM·Filed 2011·Application pending·0 cites
- 4752US8940902B2Treatment of central nervous system disordersBITNER R SCOTT·Filed 2012·Granted Jan 27, 2015·0 cites·1 claims
- 4852US8492540B21,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptorBRAJE WILFRIED·Filed 2008·Granted Jul 23, 2013·0 cites·20 claims
- 4952US8476275B2N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptorBRAJE WILFRIED·Filed 2011·Granted Jul 2, 2013·0 cites·3 claims
- 5050US2018222905A1Novel inhibitor compounds of phosphodiesterase type 10aABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →